← feed

Is NCT03236844 results overdue?

Yes — results are overdue. Primary completion was 2017-12-15; the FDAAA-801 reporting deadline (2018-12-15) passed 2745 days ago and no results are posted on ClinicalTrials.gov.

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

NCT IDNCT03236844 ↗
SponsorHoffmann-La Roche (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-12-15 (ACTUAL)
Reporting deadline2018-12-15 (completion + 365d)
Days overdue2745
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 f94216b217b57850… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03236844. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →